Risk factors for thrombosis and bleeding and their influence on therapeutic decisions in patients with essential thrombocythemia

Seminars in Thrombosis and Hemostasis

Volumn 32, Issue 4, 2006, Pages 372-380

  Griesshammer, Martin ^a,b  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b Department of Medicine III ^*  (Germany)

Author keywords

Essential thrombocythemia; Risk factors; Therapy

Indexed keywords

ANAGRELIDE; HYDROXYUREA; JANUS KINASE 2; MOLECULAR MARKER; PRV 1 PROTEIN; THROMBOPOIETIN RECEPTOR; UNCLASSIFIED DRUG;

AGE; BLEEDING; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CHINESE; CLONAL VARIATION; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; DISEASE COURSE; GENE MUTATION; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERHOMOCYSTEINEMIA; HYPERTENSION; LONG TERM CARE; PERIPHERAL ISCHEMIA; PRIORITY JOURNAL; REMISSION; REVIEW; RISK FACTOR; SMOKING; STROKE; SYSTEMATIC REVIEW; THROMBOCYTE COUNT; THROMBOCYTHEMIA; THROMBOCYTOSIS; THROMBOEMBOLISM; THROMBOPHILIA; THROMBOPHLEBITIS; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK; X CHROMOSOME INACTIVATION;

AGE FACTORS; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; FEMALE; HEMORRHAGE; HUMANS; ISOANTIGENS; JANUS KINASE 2; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; MUTATION; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; RECEPTORS, CELL SURFACE; RISK FACTORS; THROMBOCYTHEMIA, HEMORRHAGIC; THROMBOSIS;

EID: 33745728719     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-942758     Document Type: Review

References (63)

1. Finazzi G, Harrison C. Essential thrombocythemia. Semin Hematol 2005;42(4):230-238
2. Finazzi G, Barbui T. Risk-adapted therapy in essential thrombocythemia and polycythemia vera. Blood Rev 2005; 19(5):243-252
3. Barbui T, Finazzi G. When and how to treat essential thrombocythemia. N Engl J Med 2005;353(1):85-86
4. Pearson TC. The risk of thrombosis in essential thrombocythemia and polycythemia vera. Semin Oncol 2002;29(suppl 10):16-21
5. Michiels JJ, Abels J, Steketee J, van Vliet HHDM, Vuzevski VD. Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia. Ann Intern Med 1985;102:466-471
6. Michiels JJ. Normal life expectancy and thrombosis-free survival in aspirin treated essential thrombocythemia. Clin Appl Thromb Hemost 1999;5:30-36
7. Van Genderen P, Michiels JJ. Hydroxyurea in essential thrombocytosis. N Engl J Med 1995;333:802-803
8. Michiels JJ, Koudstaal PJ, Mulder AH, Van Vliet HHDM. Transient neurologic and ocular manifestations in primary thrombocythemia. Neurology 1993;43:1107-1110
9. Lahuerta-Palacios JJ, Bornstein R, Fernandez-Debora FJ, et al. Controlled and uncontrolled thrombocytosis. Its clinical role in essential thrombocythemia. Cancer 1988;61(6):1207-1212
10. Cortelazzo S, Viero P, Finazzi G, D'Emilio A, Rodeghiero F, Barbui T. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol 1990;8(3):556-562
11. Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 1995;332(17):1132-1136
12. Finazzi G, Ruggeri M, Rodeghiero F, Barbui T. Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial. Br J Haematol 2000;110(3):577-583
13. Storen EC, Tefferi A. Long-term use of anagrelide in young patients with essential thrombocythemia. Blood 2001;97(4):863-866
14. Lengfelder E, Hochhaus A, Kronawitter U, et al. Should a platelet limit of 600 × 10(9)/L be used as a diagnostic criterion in essential thrombocythaemia? An analysis of the natural course including early stages. Br J Haematol 1998;100(1):15-23
15. Chim C-S, Kwong Y-K, Lie AK-W, et al. Long-term outcome of 231 patients with essential thrombocythemia. Arch Intern Med 2005;165:2651-2658
16. Regev A, Stark P, Blickstein D, Lahav M. Thrombotic complications in essential thrombocythemia with relatively low platelet counts. Am J Hematol 1997;56(3):168-172
17. van Genderen PJ, Michiels JJ. Erythromelalgic, thrombotic and haemorrhagic manifestations of thrombocythaemia. Presse Med 1994;23(2):73-77
18. van Genderen PJ, Leenknegt H, Michiels JJ, Budde U. Acquired von Willebrand disease in myeloproliferative disorders. Leuk Lymphoma 1996;22(suppl 1):79-82
19. Griesshammer M, Bangerter M, van Vliet HHDM, Michiels JJ. Aspirin in essential thrombocythemia: status quo and quo vadis. Semin Thromb Hemost 1997;23:371-377
20. Budde U, Schaefer G, Mueller N, Egli H, Ruggeri ZM, Zimmerman TS. Acquired von Willebrand disease in the myeloproliferative syndrome. Blood 1984;64:981-985
21. Budde U, Dent JA, Berkovitz SD, Ruggeri ZM, Zimmerman TS. Subunit composition of plasma von Willebrand factor in patients with the myleproloferative syndrome. Blood 1986;68:1213-1217
22. Fabris F, Casonato A, DelBen MG, DeMarco L, Girolami A. Abnormalities of von Willebrand factor in myeloproliferative disease: a relationship with bleeding diathesis. Br J Haematol 1986;63:75-83
23. Barbui T, Barosi G, Grossi A, et al. Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica 2004;89(2):215-232
24. Colombi M, Radaelli F, Zocchi L, Maiolo AT. Thrombotic and hemorrhagic complications in essential thrombocythemia. A retrospective study of 103 patients. Cancer 1991;67(11):2926-2930
25. Besses C, Cervantes F, Pereira A, et al. Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients. Leukemia 1999; 13(2):150-154
26. Tefferi A, Fonseca R, Pereira DL, Hoagland HC. A long-term retrospective study of young women with essential thrombocythemia. Mayo Clin Proc 2001;76(1):22-28
27. Ruggeri M, Finazzi G, Tosetto A, Riva S, Rodeghiero F, Barbui T. No treatment for low-risk thrombocythaemia: results from a prospective study. Br J Haematol 1998;103(3):772-777
28. Randi ML, Rossi C, Fabris F, Girolami A. Essential thrombocythemia in young adults: treatment and outcome of 16 pregnancies. J Intern Med 1999;246(5):517-518
29. Shih LY, Lin TL, Lai CL, et al. Predictive values of X-chromosome inactivation patterns and clinicohematologic parameters for vascular complications in female patients with essential thrombocythemia. Blood 2002;100(5):1596-1601
30. Watson KV, Key N. Vascular complications of essential thrombocythaemia: a link to cardiovascular risk factors. Br J Haematol 1993;83(2):198-203
31. Jantunen R, Juvonen E, Ikkala E, Oksanen K, Anttila P, Ruutu T. The predictive value of vascular risk factors and gender for the development of thrombotic complications in essential thrombocythemia. Ann Hematol 2001;80(2):74-78
32. Jensen MK, de Nully Brown P, Thorsen S, Hasselbalch HC. Frequent occurrence of anticardiolipin antibodies, Factor V Leiden mutation, and perturbed endothelial function in chronic myeloproliferative disorders. Am J Hematol 2002; 69(3):185-191
33. Fenaux P, Simon M, Caulier MT, Lai JL, Goudemand J, Bauters F. Clinical course of essential thrombocythemia in 147 cases. Cancer 1990;66(3):549-556
34. Bucalossi A, Marotta G, Bigazzi C, Galieni P, Dispensa E. Reduction of antithrombin III, protein C, and protein S levels and activated protein C resistance in polycythemia vera and essential thrombocythemia patients with thrombosis. Am J Hematol 1996;52(1):14-20
35. Hehlmann R, Jahn M, Baumann B, Kopeke W. Essential thrombocythemia. Clinical characteristics and course of 61 cases. Cancer 1988;61(12):2487-2496
36. van Genderen PJ, Mulder PG, Waleboer M, van de Moesdijk D, Michiels JJ. Prevention and treatment of thrombotic complications in essential thrombocythaemia: efficacy and safety of aspirin. Br J Haematol 1997;97(1):179-184
37. Ruggeri M, Gisslinger H, Tosetto A, et al. Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia. Am J Hematol 2002;71(1):1-6
38. Afshar-Kharghan V, Lopez JA, Gray LA, et al. Hemostatic gene polymorphisms and the prevalence of thrombotic complications in polycythemia vera and essential thrombocythemia. Blood Coagul Fibrinolysis 2004;15(1):21-24
39. Gisslinger H, Mullner M, Pabinger I, et al. Mutation of the prothrombin gene and thrombotic events in patients with polycythemia vera or essential thrombocythemia: a cohort study. Haematologica 2005;90(3):408-410
40. Gisslinger H, Rodeghiero F, Ruggeri M, et al. Homocysteine levels in polycythaemia vera and essential thrombocythaemia. Br J Haematol 1999;105(2):551-555
41. Faurschou M, Nielsen OJ, Jensen MK, Hasselbalch HC. High prevalence of hyperhomocysteinemia due to marginal deficiency of cobalamin or folate in chronic myeloproliferative disorders. Am J Hematol 2000;65(2):136-140
42. Amitrano L, Guardascione MA, Ames PR, et al. Thrombophilic genotypes, natural anticoagulants, and plasma homocysteine in myeloproliferative disorders: relationship with splanchnic vein thrombosis and arterial disease. Am J Hematol 2003;72(2):75-81
43. Harrison CN, Donohoe S, Carr P, Dave M, Mackie I, Machin SJ. Patients with essential thrombocythaemia have an increased prevalence of antiphospholipid antibodies which may be associated with thrombosis. Thromb Haemost 2002; 87(5):802-807
44. Mohanty D, Shetty S, Ghosh K, Pawar A, Abraham P. Hereditary thrombophilia as a cause of Budd-Chiari syndrome: a study from Western India. Hepatology 2001;34:666-670
45. Janssen HL, Meinardi JR, Vleggaar FP, et al. Factor V Leiden mutation, prothrombin gene mutation and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: results of a case-control study. Blood 2000;96:2364-2368
46. Harrison CN, Gale RE, Machin SJ, Linch DC. A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications. Blood 1999;93(2):417-424
47. Chiusolo P, La Barbera EO, Laurenti L, et al. Clonal hemopoiesis and risk of thrombosis in young female patients with essential thrombocythemia. Exp Hematol 2001;29(6):670-676
48. Andreasson B, Harrison C, Lindstedt G, Linch D, Kutti J. Monoclonal myelopoiesis and subnormal erythropoietin concentration are independent risk factors for thromboembolic complications in essential thrombocythemia. Blood 2003;101(2):783
49. Kralovics R, Skoda RC. Molecular pathogenesis of Philadelphia chromosome negative myeloproliferative disorders. Blood Rev 2005;19(1):1-13
50. Cazzola M, Skoda R. Gain of function, loss of control-a molecular basis for chronic myeloproliferative disorders. Haematologica 2005;90(7):871-874
51. Goerttler PS, Steimle C, Marz E, et al. The Jak2V617F mutation, PRV-1 overexpression, and EEC formation define a similar cohort of MPD patients. Blood 2005;106(8):2862-2864
52. Teofili L, Pierconti F, Di Febo A, et al. The expression pattern of c-mpl in megakaryocytes correlates with thrombotic risk in essential thrombocythemia. Blood 2002;100(2):714-717
53. Klippel S, Strunck E, Temerinac S, et al. Quantification of PRV-1 mRNA distinguishes polycythemia vera from secondary erythrocytosis. Blood 2003;102(10):3569-3574
54. Johansson P, Ricksten A, Wennstrom L, Palmqvist L, Kutti J, Andreasson B. Increased risk for vascular complications in PRV-1 positive patients with essential thrombocythaemia. Br J Haematol 2003;123(3):513-516
55. Griesshammer M, Klippel S, Strunck E, et al. PRV-1 mRNA expression discriminates two types of essential thrombocythemia. Ann Hematol 2004;83(6):364-370
56. Goerttler PL, Marz E, Jhansson PL, et al. Thrombotic and bleeding complications in four subpopulations of patients with essential thrombocythemia defined by c-Mpl protein expression and PRV-1 mRNA levels. Haematologica 2005; 90(6):851-853
57. James C, Ugo V, Le Couedic JP, et al. A unique donal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434(7037):1144-1148
58. Wolanskyj AP, Lasho TL, Schwager SM, et al. JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. Br J Haematol 2005; 131(2):208-213
59. Antonioli E, Guglielmelli P, Pancrazzi A, et al. Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. Leukemia 2005;19(10):1847-1849
60. Campbell PJ, Scott LM, Buck G, et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 2005;366(9501):1945-1953
61. Elliott MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol 2005;128(3):275-290
62. Michiels JJ, Berneman Z, Van Bockstaele D, van der Planken M, De Raeve H, Schroyens W. Clinical and laboratory features, and pathobiology of platelet-mediated microvascular disturbances, major thrombosis and bleeding complications and the molecular etiology of ET and PV. Semin Thromb Hemost 2006;32:174-207
63. Griesshammer M, Hochhaus A. Chronische myeloproliferative Erkrankungen. In: Herausgeber M, Classen R, Dierkesmann H, et al, eds. für die deutsche Gesellschaft für Innere Medizin. Rationelle Diagnostik und Therapie in der Inneren Medizin - Leitlinien. München, Germany: Verlag Urban und Fischer, Vol. 13. 2002, Chapter B2